Listed

HeartSciences Inc.: Form 10-K for the period ended Apr 30, 2026

Filed with the SEC on Jul 23, 2026 and accepted by EDGAR at Jul 23, 2026, 16:48 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-04-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2025-05-01 to 2026-04-30$4.3kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2025-05-01 to 2026-04-30$1.8kus-gaap:CostOfRevenue
Gross profit12 months2025-05-01 to 2026-04-30$2.6kus-gaap:GrossProfit
Research and development12 months2025-05-01 to 2026-04-30$2.8mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2025-05-01 to 2026-04-30$5.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2025-05-01 to 2026-04-30−$8.4mus-gaap:OperatingIncomeLoss
Interest expense12 months2025-05-01 to 2026-04-30$753.0kus-gaap:InterestExpenseNonoperating
Income tax12 months2025-05-01 to 2026-04-30$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2025-05-01 to 2026-04-30−$9.1mus-gaap:NetIncomeLoss
Basic EPS12 months2025-05-01 to 2026-04-30−$3.48us-gaap:EarningsPerShareBasic
Operating cash flow12 months2025-05-01 to 2026-04-30−$7.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2025-05-01 to 2026-04-30$3.6kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2026-04-30$1.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Shareholders' equityAt period end2026-04-30$226.1kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001437749-26-024337. Last ingested by Listed: Oct 30, 2026, 17:27 ET. Listed shows no prices and gives no investment advice.